27 Sep 2021
|제목||PharmAbcine, non-confidential slide deck Q3 2021|
Notice of Changes:
- PharmAbcine received HREC (Human Research Ethics Committee) clearance to commence the Phase II combination trial of olinvacimab and pembrolizumab for the treatment of mTNBC (metastatic Triple-Negative Breast Cancer) in Australia
- 14 out of 36 patients have been recruited for the Phase IIa olinvacimab mono study for the treatment of Avastin refractory rGBM (recurrent Glioblastoma) in Australia and the U.S
- The competitive landscapes for the Company’s preclinical assets such as PMC-403 and PMC-309 have been updated
Thank you for your continued support.
Please check the attached file for details.